Eteplirsen Boosts Dystrophin, Function in DMD Details from 12 patients in Study 201/202 reported at AAN

“A detailed look at the trial that won eteplirsen (Exondys 51) FDA approval in Duchenne muscular dystrophy (DMD) showed that the antisense oligonucleotide drug boosted dystrophin production, and improved functional ability compared with historical controls, researchers reported here.”

For the full article published in MedPage Today –  click here.